Author:
Sumiyoshi Shutaro,Ohashi Takuma,Kubota Takeshi,Nishibeppu Keiji,Owada Kaho,Kiuchi Jun,Shimizu Hiroki,Arita Tomohiro,Iitaka Daisuke,Yamamoto Yusuke,Konishi Hirotaka,Morimura Ryo,Watanabe Kenji,Kuriu Yoshiaki,Shiozaki Atsushi,Ikoma Hisashi,Fujiwara Hitoshi,Yamaoka Nobuki,Otsuji Eigo
Abstract
Abstract
Background
Lymphovascular invasion (LVI) is a poor prognostic factor in various malignancies. However, its prognostic effect in remnant gastric cancer (RGC) remains unclear. We examined the correlation between LVI and disease prognosis in patients with T1N0-3 or T2-3N0 RGC in whom adjuvant chemotherapy was not indicated and a treatment strategy was not established.
Methods
We retrospectively analyzed patients with T1N0-3 and T2-3N0 RGC who underwent curative surgery at the Kyoto Prefectural University of Medicine between 1997 and 2019 and at the Kyoto Chubu Medical Center between 2009 and 2019.
Results
Fifteen of 38 patients (39.5%) with RGC were positive for LVI. Patients with LVI had a significantly poorer prognosis for both overall survival ([OS]: P = 0.006) and recurrence-free survival ([RFS]: P = 0.001) than those without LVI. Multivariate analyses using the Cox proportional hazards model revealed LVI as an independent prognostic factor affecting OS (P = 0.024; hazard ratio 8.27, 95% confidence interval:1.285–161.6) and RFS (P = 0.013; hazard ratio 8.98, 95% confidence interval:1.513–171.2).
Conclusions
LVI is a prognostic factor for patients with T1N0-3 or T2-3N0 RGC. Evaluating LVI may be useful for determining treatment strategies for RGC.
Publisher
Springer Science and Business Media LLC